Rani Therapeutics Holdings, Inc. (RANI) stock
Close on Nov 11, 2026Market cap $79.18MP/E –Yield –
Rani Therapeutics Holdings, Inc. grew revenue 448.7% to $6.58M over the twelve months to Sep 30, 2026. Free cash flow was -$23.22M. At the latest close the market valued the company at $79.18M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $79.18M
- P/E ratio
- –
- Price to sales
- 12.03
- Price to book
- 2.33
- Dividend yield
- –
- Free cash flow yield
- -29.33%
Fundamentals
- Revenue
- $6.58M
- Net income
- -$32.46M
- EPS, diluted
- -$0.45
- Free cash flow
- -$23.22M
- Book value per share
- $0.17
- Diluted shares
- 199M
Trading
- Next earnings
- Mar 25, 2027 (estimated, during market hours)
- Previous close
- $0.56
- Open
- $0.57
- Day's range
- $0.55 – $0.58
- Volume
- 343,158
- Average volume (20 days)
- 477,705
- Beta (5 years)
- 0.86
- 52-week range
- $0.51 – $2.15
- RSI (14 days)
- 39.2
- Volatility (1 year)
- 83.9%
- Relative volume
- 0.49×
- WACC
- 9.2%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RANI | S&P 500 | Difference | RANI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.9% | -2.4% | −26.5 pts | ||
| 3 months | -27.6% | -1.2% | −26.5 pts | ||
| Year to date | -57.9% | +12.3% | −70.2 pts | ||
| 1 year | -70.7% | +12.4% | −83.2 pts | ||
| 3 years | -71.3% | +78.8% | −150.1 pts | -34.0% | +21.4% |
| 5 years | -98.0% | +75.2% | −173.2 pts | -54.3% | +11.9% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rani Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Rani Therapeutics
Pharmaceutical Preparations
Rani Therapeutics is a clinical-stage biotherapeutics enterprise that develops oral delivery technologies for biologics and drugs, designed to replace traditional subcutaneous and intravenous injections. The company focuses on its proprietary, drug-agnostic RaniPill platform, which includes the RaniPill GO microtablet system and the RaniPill HC high-capacity liquid formulation capsule. Its therapeutic pipeline spans multiple indications, including obesity, inflammatory disorders, and rare diseases, featuring active candidates such as RT-114, RT-116, RT-111, and RT-117. Intended customers and commercial targets comprise partner biopharmaceutical firms seeking oral delivery mechanisms for proprietary compounds, alongside eventual end-users including patients, prescribing clinicians, and healthcare networks.
Company profile, executives and historyRani Therapeutics stock: common questions
What is Rani Therapeutics's stock price?
RANI closed at $0.57 on Nov 11, 2026, up 1.41% on the day. Over the past 52 weeks it traded between $0.51 and $2.15.
What is Rani Therapeutics's market cap?
Rani Therapeutics was worth $79.18M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RANI's P/E ratio?
Rani Therapeutics lost money over fiscal 2025 (diluted EPS -$0.45), so it has no meaningful P/E ratio.
How much revenue does Rani Therapeutics make?
Rani Therapeutics reported revenue of $6.58M for the twelve months to Sep 30, 2026, up 448.7% from a year earlier.
Does Rani Therapeutics pay a dividend?
No. Rani Therapeutics has not paid a cash dividend over the last twelve months.
When does Rani Therapeutics report earnings next?
Rani Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RANI stock performed over the past year?
Including dividends, RANI returned -70.7% over the past year, against +12.4% for the S&P 500.
How many RANI shares are sold short?
8M shares were sold short at the latest FINRA report, 8.49% of the float, or 17.2 days of average trading volume.
Who are Rani Therapeutics's competitors?
Companies most similar to Rani Therapeutics by business, industry and size include ALMS, ACRS, PTN, TVRD, CAMP.
See a number that looks wrong?